The Health and Social Care Act 2012 (Commencement No. 12) Order 2026 is a narrow but important statutory instrument in the NHS legal timetable. Made on 15 July 2026 and signed by Health Minister Stephen Kinnock for the Department of Health and Social Care, it fixes 1 October 2026 as the date when section 208 of the 2012 Act comes into force, so far as any part of that section remained uncommenced. For policy readers, the key point is that this Order does not create a fresh policy in its own right. It switches on a provision already approved in primary legislation, turning dormant statutory text into live law.
According to the explanatory note published on legislation.gov.uk, section 208 amends the National Health Service Act 2006 so that the NHS Commissioning Board, now NHS England, may establish lists of Local Pharmaceutical Service performers and of people who assist pharmaceutical contractors in providing pharmaceutical services. In plain terms, the provision gives NHS England a clearer legal basis to identify and manage who is formally recorded for work connected to Local Pharmaceutical Services. That places performer list arrangements on a firmer statutory footing within NHS administrative oversight.
The immediate institutional effect falls on NHS England rather than on patients. From 1 October 2026, NHS England will be able to rely on section 208 as commenced law when operating arrangements for these categories of pharmaceutical staff and assistants. The drafting also matters. The Order brings section 208 into force 'so far as it is not already in force', which means it captures only any remaining dormant parts of the section. It does not disturb anything that earlier commencement orders had already activated.
This is the twelfth commencement order made under the Health and Social Care Act 2012. As the note accompanying the instrument records, earlier provisions of the Act were brought into force through a series of orders made between 2012 and 2018, while some provisions started on the day the Act was passed. That staging is common in large health statutes. Ministers often use commencement orders to match legal start dates to administrative readiness, rather than bringing every clause into effect at once. Here, the Department has chosen 1 October 2026 as the operative date for section 208.
The explanatory note is also clear about what this instrument does not do. No separate full impact assessment has been prepared for the Order itself, because the commencement measure is said to have no direct impact on the private sector or civil society organisations. Instead, the full assessment sits with the wider Health and Social Care Act 2012 package. That should be read carefully. The absence of a new impact assessment does not mean the commencement is negligible. It means the policy case was assessed at Act level, while this instrument is limited to legal timing and implementation.
For NHS managers, pharmaceutical contractors and those working within Local Pharmaceutical Services, the practical question is what changes on 1 October 2026. The clearest answer from the text is that NHS England gains the statutory footing to establish the relevant performer lists, including for those assisting contractors in service delivery. The Order does not, by itself, set out detailed eligibility tests, processes or sanctions. Those matters sit elsewhere in the legislative and administrative scheme. This instrument is therefore best understood as a commencement step with real administrative effect: narrow in form, but significant for how pharmaceutical service workforce controls are anchored in law.